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Abstract 
Luteinizing hormone (LH) and human chorionic gonadotropin (hCG) are members of the 
gonadotropin family and are vital for fertility in animals. Both LH and hCG bind to the 
luteinizing hormone receptor (LHR), found only in gonadal cells such as the Leydig cells of the 
testis and the granulosa and theca cells of the ovary. Binding of the hormone to its receptor 
causes production of the steroid hormones testosterone and estrogen. By ablating cells that 
express LHR, the production of sex steroids would be terminated, leading to a loss in fertility. 
The overall goal of the project is to create a nonsurgical, single-dose sterilant for cats and dogs 
by ablating these cells. One way to target these cells is the creation of a fusion protein that 
includes a toxin targeted to these cell types. This paper will focus on determining the efficiency 
in production of these fusion proteins in cell culture. Diphtheria toxin (DT) and Pseudomonas 
endotoxin A (PE) are both suitable toxins known to be successfully inserted into fusion proteins. 
By replacing the receptor-binding domain in these toxins with hCG, the toxin will be ineffective 
in all cells except those expressing LHR. To test how much fusion protein is produced in cells, 
Chinese hamster ovary (CHO) cells and alpha mouse liver (AML) cells were used to produce 
fusion proteins. While the total protein concentration was higher in the transfection media of 
AML cells compared to CHO cells, no hCG was detected in the AML transfection media. 
Therefore, AML cells may not produce sufficient amounts of the fusion protein to quantify. CHO 
cells were used to produce six fusion proteins using both DT and PE. The fusion proteins that 
contain DT were expressed at lower concentrations than yhCG alone, while the fusion proteins 
containing PE could not be detected at all in the CHO media. These results suggest that the 
addition of the toxin to hCG decreases either transfection and/or production efficiency and that 
PE may have an adverse effect on cell health, which would lead to poor expression. 
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Introduction 
Luteinizing Hormone, the Luteinizing Hormone Receptor, and Human Chorionic Gonadotropin 
 The anterior pituitary gland secretes two gonadotropins: luteinizing hormone (LH) and 
follicle stimulating hormone (FSH). These hormones are produced starting at puberty and act on 
the gonads of both sexes. LH binds to the luteinizing hormone receptor (LHR), found only in 
theca and granulosa cells of the ovaries and Leydig cells in the testes. LH is necessary for the 
production of steroid hormones such as testosterone and estrogen (1). LH is required for both 
spermatogenesis and ovulation. If LHR were eliminated, there would be a reduction and most 
likely termination of the production of sex hormones. This lack of hormones would then cause 
infertility, due to the lack of mature sperm and eggs.  
 Human chorionic gonadotropin (hCG) is another gonadotropin; however, hCG is 
synthesized in the placenta of primates and equines, not in the anterior pituitary gland. All three 
of the gonadotropins share similar structures, in that they are all glycosylated heterodimers (2). 
All gonadotropins share a common alpha subunit while the beta subunits are specific to each 
hormone. The hCG beta subunit contains a unique addition to the C-terminus in the form of a 30 
amino acid residue extension (3). It has been demonstrated that this can increase the half-life of 
this hormone in vivo, as there is no role for it in the activity of the hormone (4,5). Glycosylated 
hCG has a total molecular weight of 38,000 kDa. The amino acid sequence for hCG shares a 
high amount of homology with the sequence for LH (2). This leads to the ability for hCG to bind 
to LHR with an even higher affinity than LH.  
 While hCG has a heterodimeric structure, it was shown that a single chain homolog, in 
which the alpha and beta subunits are synthesized together, has the same binding affinity to LHR 
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as native hCG. This single chain or yoked hCG (yhCG) is used in this experiment to ensure that 
both the alpha and beta subunits are produced by the cells (6).  
hCG-Toxin Fusion Proteins for Cell Ablation 
Immunotoxins are modified protein toxins that are targeted to act on a certain type of cell. 
This specificity comes from the replacement of the native receptor-binding domain with a 
antibody or hormone that targets one type of cell. The toxin can then be internalized by that cell 
type and act on it, leaving cells without the specific receptor unharmed. This method of cell 
targeting has been used in clinical trials for targeting different types of tumor cells as a possible 
cure for cancer (7). In this project, the receptor-binding of the toxins are replaced with yhCG, so 
that the toxins will only be able to act on cells that contain LHR. Therefore, the toxin action will 
be targeted to gonadal cells expressing LHR and halting the production of sex steroids. This will 
in turn cause infertility due to lack of mature gametes.  
Two toxins are used in this project to create fusion protein constructs and to test in cell 
culture. The two toxins are DT and PE, and these were chosen because of two reasons. The first 
reason is that while both toxins contain a catalytic (C) domain, a translocation (T) domain, and a 
receptor-binding (R) domain, the orders of these domains are different between the toxins. In 
DT, the R domain is found at the C terminus of the sequence (8), while the R domain of PE is 
found at the N-terminus of the sequence (9,10). There is a possibility that the difference in R 
domain location could lead to a difference in binding of the toxin to the cell receptor. By testing 
both of the toxins, the potential difference can be accounted for.  
Another reason for choosing the two toxins is the difference in their intracellular 
traficking. DT attaches to the target cell via the R domain, where the toxin is cleaved between 
the C and T domains, leaving a disulfide bond connecting the two domains. The cleaved toxin is 
 7 
brought into the cell through clathrin-coated pits, which mature into early endosomes. A channel 
is formed in the endosome by the T domain, which causes the C domain to translocate across the 
membrane. When in the cytoplasm, the catalytic domain is able to inhibit protein synthesis by 
the ribosylation of an elongation factor (eEF-2), resulting in cell death (11) (Figure 1). DT has 
such a high level of cytotoxicity that one molecule of the C domain has been found to be 
adequate to kill the cell (12). 
  
Figure 1. Mode of action of DT. Adapted from reference 7. 1. DT before binding to the cell. C and T domain 
connected by an extra disulfide bond. 2. R domain binds to the cell surface receptor. 3. The bond between the C and 
T domains is cleaved, leaving only a disulfide bond connecting them. 4. The toxin is internalized through clathrin-
coated pits, which turn into early endosomes. 5. In the early endosome, the T domain creates a channel in the 
membrane and the C domain is translocated into the cytoplasm. 6. The C domain inhibits eukaryotic elongation 
factor-2 (eEF2) through ADP ribosylation to cause cell death by halting protein synthesis. 
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 PE is also internalized by clathrin-coated pits after binding to its cell surface receptor and 
the terminal lysine is removed from the REDLK signal sequence. In the early endosome, the 
toxin is cleaved to yield an active fragment containing the C (III) domain and two-thirds of the T 
(II) domain. This fragment is transported through the trans-Golgi network, where the REDL 
sequence binds to the KDEL receptor and is sent to the endoplasmic reticulum. Sequences in 
domain II cause the retro-translocation to the cytoplasm, when the catalytic domain targets and 
inhibits eEF2 to cause cell death. (7) (Figure 2).  
 
Figure 2. Mode of action of PE adapted from reference 7. 1. PE sequence before binding to the receptor. 2. The 
terminal lysine is removed from the signal sequence and the toxin binds to the cell receptor through domain I. 3. The 
toxin is internalized via clathrin-coated pits. 4. The C domain and two-thirds of the T domain are cleaved from the 
rest of the toxin. 5. The active fragment is transported to the trans-Golgi network. 6. The fragment is routed to the 
ER through the REDL signal sequence and is retro-translocated to the cytoplasm. 7. PE targets eEF2 to inhibit 
protein synthesis and cause cell death.  
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Six toxin constructs were created (Figure 3) so that testing can be done to determine 
which immunotoxin has the best activity. DT and PE have both been previously used to generate 
fusion proteins for targeting tumors expressing different receptors (7,13,14,15). Other differences 
between the constructs include the presence of an additional CTP sequence between the toxin 
and the yhCG in order to allow for more flexibility and possibly better folding. Also, in the PE 
constructs, the substitution of a KDEL sequence in the place of the native REDLK sequence will 
be created. This replacement has been shown to increase PE’s cytotoxicity, which is why it is of 
interest (15). 
   
Figure 1. Schematic of hCG-toxin fusion proteins. These constructs were generated by Stacey 
McGee in the Narayan lab.  
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CHO and AML Cell Lines 
 CHO cells are a commonly used cell type in biological laboratories because they are easy 
to maintain and produce large amounts of protein (16). Therefore, they are an ideal cell line to 
use in this project to produce the fusion proteins. These cells are used as a control line because of 
their known protein production. To assist in discovering the effects of these fusion proteins on 
target tissues, AML12 cells will also used as a production cell line. In the final product, the 
fusion toxin construct will be targeted to the liver, for protein expression and secretion into 
circulation. Therefore, the potential effects of the toxin on the liver are of interest, as well as 
determining whether these liver cells are capable of producing the toxin.  
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Goal 
The goal of the project is to create a nonsurgical, single-dose sterilant for cats and dogs. 
The specific goal of my portion of the project is to determine the amount of toxin fusion proteins 
produced by AML and CHO cells. Before testing these fusion proteins in murine animals, they 
must be tested in cell culture to determine their effects. The amount of fusion protein produced 
by the cells may vary with cell type, so two different lines are used. AML are used to produce 
the fusion proteins because liver cells will be targeted in the in vivo studies. CHO cells are used 
as a control because they are known to produce large amounts of proteins. 
Experimental Methods 
Cell lines, media, and culture conditions 
CHO and AML12 cells were purchased from American Type Tissue Culture.  CHO cells 
were maintained in DMEM/F12 media with 10% fetal bovine serum at 370C with 5% CO2. 
AML12 cells were maintained in DMEM/F12 media with 10% fetal bovine serum and 
dexamethasone at 370C with 5% CO2. 
Transient transfection of yhCG and fusion proteins 
In order to transiently transfect cell lines with desired plasmids, Lipofectamine 3000 
transfection reagents were used. Cells were grown in 10 cm dishes until 70-80% confluency in 
their appropriate media. Just before transfection, the serum-containing media was replaced with 
serum-free media. 750 µl of Optimem Reduced Serum Media was mixed with 15ug of construct 
DNA and 30 µl of P3000 reagent. A separate solution of 750 µl Optimem and 22.5 µl  
Lipofectamine reagent was also prepared. These two solutions were mixed and allowed to sit for 
5 minutes. Then the mixture was pipetted onto the cell plates and allowed to incubate for 5 
hours. The media was removed and replaced with complete, serum-containing media, and the 
cells were incubated overnight. Then, the complete media was replaced with serum-free media 
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and the cells were incubated for 48 hours. After 48 hours, the serum-free media was collected. 
Cells were transfected with yhCG or one of the following fusion toxin constructs: DT-yhCG, 
DT-CTP-yhCG, yhCG-PE, yhCG-PE-CTP, yhCG-PE KDEL, and yhCG-PE-CTP KDEL. 
Concentration of Transfection Media 
To concentrate the serum-free media collected from the transfection, first, 500 µl were 
aliquoted to store as an unconcentrated source. The rest of the media (9.5mL) was loaded into 
Vivaspin 6 centrifugal concentrators (GE Healthcare). For the yhCG-transfected cells, 
concentrators with a 10 kDa MWCO were used while concentrators with a 30 kDa MWCO were 
used for the toxin constructs. The concentrators were centrifuged at 10,000 x G for 30 minutes, 
or until the media had been concentrated to 200 µl. The media was aliquoted and stored at -200C.  
For one sample of the AML media, a portion was concentrated additionally using a 
vacuum concentrator to ensure a detectable amount of protein was in the sample. The  media was 
centrifuged for 30 minutes, then collected.  
Protein Assay 
 The total protein concentration of the media was assayed using a BioRad protein assay. 
10 µl of BSA standards and concentrated transfection media was added to wells on a 96 well 
assay plate. 200 µl of BioRad dye reagent (1:5 in water) was added to the samples. The plate was 
incubated at room temperature for 5 minutes and read at 595 nm.  
Western blot analysis of toxin expression 
The standard protocol of western blot analysis was used to detect expression of the toxins 
(17). A 10% Laemmli discontinuous gel was used.  On the gel, 30 µl samples of concentrated 
media from transient transfections of AML and CHO cells were loaded into the wells.  The 
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proteins were transferred to a PVDF membrane. A CTP antibody was used to detect yhCG and 
the fusion proteins. 
ELISA analysis of total hCG production 
An ELISA kit (Sigma-Aldrich, SE120063) was used to quantify the amount of hCG in 
the transfected media. hCG MAb coated wells were filled with 50 µl of hCG standards, control 
and samples of CHO and AML media from transient transfections of yhCG and the fusion 
proteins. Then 100 uL of enzyme conjugate was added to all wells. The plate was covered and 
incubated with gentle agitation for 1 hour at room temperature. After 1 hour, the liquid was 
removed from the wells, which were rinsed. 100 µl of TMB substrate was added and incubated 
for 10 minutes. Then 50 µl of stop solution were added to the wells and mixed. The wells were 
read at 450nm.  
Results and Discussion 
 
 Because CHO cells are known to be reliable producers of proteins, both AML and CHO 
cells were transfected with yhCG to determine the efficiency of protein production in AML cells. 
The protein assay shown in Figure 4 indicates that the AML media had a higher total protein 
content than the CHO cells. However, the protein assay is not specific for the target protein, 
yhCG. Therefore, western blot analysis using a CTP antibody specific for hCGβ was performed 
to quantify the relative amounts of yhCG that had been produced by the cells. The results of the 
western blot showed bands in both the hCG control and CHO transfection media lanes, but not in 
the AML transfection media lanes (Figure 5). The difference in band size can be due to 
difference in glycosylation in the samples, and because in the hCG lane, the α and β subunits are 
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separated. Therefore, it was determined that although the AML cells had a higher total protein 
concentration, the transfection was not successful enough to give a detectable amount of yhCG.  
 
Figure 4. Total protein concentration in media of CHO and AML cells transfected with yhCG. Media was 
concentrated and assayed for total protein.  
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Figure 5. Western blot analysis of CHO and AML yhCG transfection medias with CTP antibody. Lane 1 contains 
30ng of pure hCG. Lane 2 contains AML transfection media concentrated using column concentrators (10.4 µg total 
protein). Lane 3 contains AML transfection media concentrated using column concentrators and vacuum 
concentration (54 µg total protein). Lane 4 contains column concentrated CHO transfection media (26.1 µg total 
protein). 
Because of the findings of the western blot analysis, CHO cells were used for the rest of 
the project to produce the fusion proteins. Transient transfections with each construct were 
performed in CHO cells in order to have sufficient protein for analysis. Next, the total protein 
content of each sample of concentrated transfection media was determined (Figure 6). The  
transfections with the different constructs produced a similar amount of total protein, with both 
DT and PE constructs producing between 4000 and 5000 mg/ml of total protein. We would 
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expect that the amount of yhCG/fusion protein produced should be proportional to the total 
protein concentration.  To determine this, an ELISA was performed that is specific for hCG. 
 
  
Figure 6. Total protein concentration in CHO transfection media. The media was collected, and concentrated, then 
assayed to determine protein production.  
Because all of the constructs contain yhCG as the R domain, the ELISA should be able to 
detect all of the constructs, no matter what toxin was attached. The results for the ELISA can be 
found in Figure 7. Surprisingly, only the yhCG, DT, and DT CTP produced detectable levels of 
hCG. All four PE constructs resulted in levels of hCG-toxin that was below the limit of detection 
of the ELISA. Even the DT constructs had a much lower concentration of hCG than the yhCG, 
which suggests that either the addition of the toxin to the protein may inhibit synthesis in some 
way or that the fusion with the toxin prevents the antibody used in the ELISA from detecting 
hCG.  This data may suggest that PE has a negative effect on the cells when produced, which 
would lead to lower fusion protein expression. 
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Figure 7. Concentration of hCG in media from CHO cells transfected with the various constructs. Media was 
collected, concentrated and the concentration of yhCG or fusion proteins was measured using a hCG specific ELISA 
kit.  
This project determined that CHO cells can be used to produce hCG-toxin fusion proteins 
in cell culture, while AML cells were not able to produce a detectable amount of the protein. 
However, when the amount of fusion protein was quantified using ELISA, the fusion proteins 
containing DT were present in a much lower amount than yhCG, while those containing PE were 
not detectable in the cell media at all. 
Future studies will be done to optimize the transfection conditions for CHO and AML 
cells to increase the efficiency of fusion protein production. Once the fusion proteins are 
produced, binding assays will be performed to determine whether or not these fusion proteins 
can target the cells that express LHR. This will also determine if the fusion proteins have the 
same affinity for LHR as native hCG. By completing these binding assays, we hope to discover 
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whether or not the fusion proteins can successfully target and ablate the gonadal cells they are 
intended to destroy. 
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